MANNER: Effectiveness of Mobile-health Self Management on Quality of Life of Patients Undergoing Chemotherapy

Sponsor
Universitas Muhammadiyah Yogyakarta (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05881070
Collaborator
(none)
50
1
3.5

Study Details

Study Description

Brief Summary

The study will design and evaluate the use of mobile-health based self-management on self-efficacy and quality of life of patients undergoing chemotherapy.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Mobile-health self management
N/A

Detailed Description

The study will design and evaluate the use of mobile-health based self-management on self-efficacy and quality of life of patients undergoing chemotherapy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Mobile-health Self Management on Quality of Life of Patients Undergoing Chemotherapy
Anticipated Study Start Date :
Jun 15, 2023
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mobile health self-management

Behavioral: Mobile-health self management
Mobile-health self management

Outcome Measures

Primary Outcome Measures

  1. Patient's Quality of life [Four weeks]

    The patient's quality of life will be assessed before (T0) and after intervention (T1). The measurement will use EORTC. The score will range from 0-100, where higher score reflects a better quality of life.

  2. Patient's Self-efficacy [four weeks]

    The patients self-efficacy will be measured pre and post intervention. The measurement will use the Self-Efficacy for Managing Chronic Disease Scale. The scale has been widely used in cancer setting. Respondents will rate their confidence to perform six self-management behaviours (1 = 'not at all confident' to 10 = 'totally confident'). A mean score is calculated (range 1 to 10). A high score indicates high self-efficacy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • adult patients diagnosed with cancer

  • patients who use smart phone

Exclusion Criteria:
  • patients with cancer with comorbidity

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Universitas Muhammadiyah Yogyakarta

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Erna Rochmawati, Associate Professor, Universitas Muhammadiyah Yogyakarta
ClinicalTrials.gov Identifier:
NCT05881070
Other Study ID Numbers:
  • Manner and QOL
First Posted:
May 30, 2023
Last Update Posted:
May 30, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of May 30, 2023